Stock A256840 BNC KOREA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

BNC Korea Co., Ltd. Stock

Equities

A256840

KR7256840000

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-21 pm EDT 		5-day change 1st Jan Change
6,360 KRW +2.75% Intraday chart for BNC Korea Co., Ltd. -5.92% +71.89%
Mar. 25 Hankook Korus Pharm Co., Ltd. announced that it has received KRW 2 billion in funding from BNC Korea Co., Ltd. CI
2023 NovMetaPharma Co., Ltd. announced that it has received KRW 6.99999258 billion in funding from BNC Korea Co., Ltd. CI

Financials

Sales 2022 42.3B 30.71M Sales 2023 81B 58.8M Capitalization 246B 178M
Net income 2022 -44.7B -32.46M Net income 2023 25.69B 18.65M EV / Sales 2022 4.78 x
Net cash position 2022 105B 76.18M Net cash position 2023 80.08B 58.14M EV / Sales 2023 2.04 x
P/E ratio 2022
-5.72 x
P/E ratio 2023
11.1 x
Employees 174
Yield 2022 *
-
Yield 2023
-
Free-Float 77.99%
More Fundamentals * Assessed data

Chart BNC Korea Co., Ltd.

Dynamic Chart

Latest news about BNC Korea Co., Ltd.

Hankook Korus Pharm Co., Ltd. announced that it has received KRW 2 billion in funding from BNC Korea Co., Ltd. CI
NovMetaPharma Co., Ltd. announced that it has received KRW 6.99999258 billion in funding from BNC Korea Co., Ltd. CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 6.99999258 billion in funding from BNC Korea Co., Ltd. CI
BNC Korea Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
BNC Korea Co., Ltd. agreed to acquire a 63.2% stake in Dong-in Biotech Co., Ltd. from Jo Gil-nam and others for KRW 12 billion. CI
Clips Co., Ltd. announced that it expects to receive KRW 2.50003 billion in funding from EuBiologics Co., Ltd., SK bioscience Co.,Ltd., BNC Korea Co., Ltd. CI
BNC Korea Co., Ltd.(KOSDAQ:A256840) added to S&P Global BMI Index CI
BNC Korea Co., Ltd. announced that it has received KRW 40.000011929 billion in funding from a group of investors CI
BNC Korea Co., Ltd. announced that it expects to receive KRW 40.000011929 billion in funding from a group of investors CI
BNC Korea Co., Ltd completed the acquisition of NH Special Purpose Acquisition 11 Co., Ltd. in a reverse merger transaction. CI
BNC Korea Co., Ltd. entered into an agreement to acquire NH Special Purpose Acquisition 11 Co., Ltd. in a reverse merger transaction. CI
Myfirstasset Asset Management Co., Ltd acquired 4.4% stake in BNC Korea Co.,Ltd. from 2010 KIF-Premier Fund, fund managed by Premier Partners, LLC for KRW 2.5 billion. CI
NH Investment and Mirae Asset acquired 2.21% stake in BNC Korea Co.,Ltd. from Doo-Yeong Shin for KRW 1.2 billion. CI
Kolon 2015 Secondary Market, a fund of Kolon Investment, Inc. acquired 2.21% stake in BNC Korea Co.,Ltd from 2010 KIF-Premiere Investment Union for KRW 1.5 billion. CI
More news

Quotes and Performance

1 day+2.75%
1 week-5.92%
Current month-14.29%
1 month-28.05%
3 months+85.96%
6 months+104.83%
Current year+71.89%
More quotes

Highs and lows

1 week
6 040.00
Extreme 6040
6 920.00
1 month
5 830.00
Extreme 5830
8 950.00
Current year
3 325.00
Extreme 3325
9 410.00
1 year
2 865.00
Extreme 2865
9 410.00
3 years
2 865.00
Extreme 2865
70 500.00
5 years
1 100.00
Extreme 1100
70 500.00
10 years
1 100.00
Extreme 1100
70 500.00
More quotes

Managers and Directors - BNC Korea Co., Ltd.

Managers TitleAgeSince
Wan-Kyu Choi CEO
 Chief Executive Officer 66 19-11-18
Seong-Myeong Hwang SAM
 Sales & Marketing 54 -
Jae-Myeong Yang AUD
 Comptroller/Controller/Auditor 73 19-10-10
Members of the board TitleAgeSince
Wan-Kyu Choi CEO
 Chief Executive Officer 66 19-11-18
Man-Seok Jo BRD
 Director/Board Member 59 19-10-10
Seong-Won Hong BRD
 Director/Board Member 73 19-10-10
More insiders

Quotes

Date Price Change Volume
24-04-22 6,360 +2.75% 1,628,283
24-04-19 6,190 -2.67% 1,591,355
24-04-18 6,360 +4.43% 1,917,518
24-04-17 6,090 -4.55% 7,994,528
24-04-16 6,380 -5.62% 2,138,381

End-of-day quote Korea S.E., April 21, 2024

More quotes

Company Profile

BNC Korea Co. Ltd, formerly NH Special Purpose Acquisition 11 Co., Ltd., is a Korea-based company principally engaged in the manufacture and sale of biopharmaceuticals. The Company's main products include hyaluronic acid (HA) fillers, collagen wound dressings, antiadhesion materials and collagen tissue supplements, and others. In addition, the Company produces and sells cosmetics, medicines and medical devices, among others.
Sector
Pharmaceuticals
Calendar
2024-05-12 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
BNC KOREA CO., LTD. Stock BNC Korea Co., Ltd.
+71.89% 306M
CSL LIMITED Stock CSL Limited
-2.68% 85.68B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+5.53% 41.4B
BIOGEN INC. Stock Biogen Inc.
-24.99% 28.22B
UCB Stock UCB
+54.63% 24.64B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-7.19% 16.98B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-34.20% 13.29B
INCYTE CORPORATION Stock Incyte Corporation
-17.31% 11.66B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.43% 11.65B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-1.57% 8.18B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A256840 Stock